Prevalence of Obstructive Sleep Apnoea and Its Association With Atherosclerotic Plaques in a Cohort of Subjects With Mild–Moderate Cardiovascular Risk

Esther Sapiña-Beltrán a, b, Esther Gracia-Lavedan a, b, Gerard Torres a, b, Anna Michela Gaeta a, Judith Paredes c, Ana Mayoral c, Elvira Fernández d, Marcelino Bermúdez-López d, José Manuel Valdivielso d, Cristina Farrás-Salles e, Reinald Pamplona f, Albert Lecube g, Jordi de Battle a, b, Ferran Barbé a, b, Mireia Dalmases a, b, *, on behalf of ILERVAS group

a Hospital Universitari Arnuat de Vilanova and Santa Maria, Group of Translational Research in Respiratory Medicine, IRB Lleida, Universitat de Lleida, Av. Rovira Roure 80, 25198 Lleida, Spain
b Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Av. Monforte de Lemos, 3-5, Pabellón 11, 28029 Madrid, Spain
c Oxygen Salud, Homecare Provider, C/ Pere IV, 453, 08020 Barcelona, Spain
d Vascular and Renal Translational Research Group, IRBLleida, RedInRen-ISCIII, Av. Rovira Roure 80, 25198 Lleida, Spain
e Primary Care ABS Balsófa – Pardinyes – Secá de Sant Pere, Av. Alcalde Recasens s/n, 25005 Lleida, Spain
f Department of Experimental Medicine, University of Lleida-Lleida Biomedical Research Institute (UAL-IRBLleida), Av. Rovira Roure 80, 25198 Lleida, Spain
g Endocrinology and Nutrition Department, Hospital Universitari Arnuat de Vilanova, Obesity, Diabetes and Metabolism Research Group (ODIM), Institut de Recerca Biomédica de Lleida (IRBLleida), Universitat de Lleida, Av. Rovira Roure 80, Lleida, Spain

A R T I C L E   I N F O

Article history:
Received 16 November 2020
Accepted 25 January 2021
Available online 13 February 2021

Keywords:
Atherosclerotic plaque
Cardiovascular risk factors
Obstructive sleep apnoea
Prevalence

A B S T R A C T

Introduction: Classic cardiovascular risk factors do not explain all the cardiovascular events. Obstructive sleep apnoea (OSA) has been proposed as a potential and prevalent cardiovascular risk factor. Our study aimed to describe the prevalence of OSA in a middle-aged cohort with mild–moderate cardiovascular risk and evaluate its association with atherosclerotic disease.

Methods: This is an observational cross-sectional ancillary study of the ILERVAS project which was aimed to study subclinical arterial disease in a cohort with mild–moderate cardiovascular risk. In a sample of consecutive subjects, we performed a sleep study and evaluate OSA prevalence and its association with carotid and femoral atheroma plaques and atherosclerotic burden.

Results: Overall, 966 subjects with a median age of 57 years (25–75th percentile; 52–62) and a body mass index (BMI) of 28.5 kg/m² (25.6–31.6) were included. Of these, 72.6% (60.7%–75.3%) had OSA (apnoea–hypopnoea index (AHI) ≥ 5/h); 35.7% (32.8%–38.8%) had mild OSA (AHI 5–14.9/h) and 36.9% (33.9%–39.9%) had moderate/severe OSA (AHI ≥ 15/h). Mean oxygen saturation and the percentage of time with oxygen saturation <90% (CT90) were associated with atherosclerotic burden (e6 (95%CI) 0.932 (0.892, 0.974); 1.005 (1.002, 1.009), respectively) and total plaque (OR (95%CI) 0.86 (0.797,0.971); 1.013 (1.004,1.021), respectively). No association with the AHI or oxygen desaturation index was found.

Conclusions: This study confirms a high prevalence of OSA in patients with mild–moderate cardiovascular risk and shows an association between atherosclerotic burden, total and femoral plaque with CT90 and mean oxygen saturation, suggesting the importance of OSA-related hypoxaemia in the induction of atherosclerotic disease.

© 2021 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.

Abbreviations: AHI, apnoea–hypopnoea index; BMI, body mass index; CVD, cardiovascular disease; ESS, Epworth sleepiness scale; ODI, oxygen desaturation index; OSA, obstructive sleep apnoea.

* Corresponding author.
E-mail address: mdalmases.illeida.ics@gencat.cat (M. Dalmases).
Introduction

Classic cardiovascular risk factors do not explain all the cardiovascular events that occur,\textsuperscript{1,2} and it is possible that other unknown cardiovascular risk factors may exist. In this sense, obstructive sleep apnoea (OSA) has been proposed as a new potential and prevalent cardiovascular risk factor.\textsuperscript{3,4} OSA is characterized by partial or complete episodes of collapse of the upper airway during sleep that cause intermittent hypoxia, hypercapnia, sleep fragmentation and exaggerated fluctuations in heart rhythm, blood pressure and intrathoracic pressure.\textsuperscript{5,6} In turn, these physiological disruptions can result in excessive daytime sleepiness, poor quality of life and cardiometabolic alterations.\textsuperscript{5,6}

Several studies associated OSA to cardiovascular risk factors and support that OSA contributes to the pathogenesis of cardiovascular disease.\textsuperscript{1} Intermittent hypoxia and intrathoracic pressure swings have been associated with the initiation and progression of atherosclerosis.\textsuperscript{7,8} In contrast, some authors suggest that OSA may require other risk factors for the development of atherosclerotic plaques.\textsuperscript{9} Therefore, the impact of OSA on atherosclerosis and its interaction with other cardiovascular risk factors is not well known.

A higher prevalence of OSA has been described in individuals with cardiovascular conditions than in healthy adults;\textsuperscript{10} furthermore OSA prevalence in cohorts with cardiovascular risk factors has triggered great interest.\textsuperscript{11}

OSA and snoring have been associated with atherosclerotic plaque, especially in the carotid\textsuperscript{12,13}; nevertheless, there are few studies with controversial data, and evidence is limited.

In this context, the current study aimed to describe the prevalence of OSA in a cohort of middle-aged subjects with mild–moderate cardiovascular risk and evaluate whether there is an association between polygraphy variables and the presence of atherosclerosis. Considering the controversial role of snoring on carotid but not femoral atherosclerosis, both territories were explored to assess potential differences.

Methods

Design and Study Population

This is an ancillary study of the ILERVAS project (NCT03228459) aimed to evaluate subclinical arterial disease and hidden kidney disease in a cohort with mild–moderate cardiovascular risk.\textsuperscript{14} For more detailed information on the ILERVAS project see supplemental material.

The current study is an observational cross-sectional study of the ILERVAS cohort performed between March 2017 and September 2018. The aim is to analyze the prevalence of OSA in middle-aged subjects with mild–moderate cardiovascular risk and evaluate whether there is an association between OSA, the atherosclerotic burden and the presence of plaque in the different arterial territories. The ethics committee of our hospital approved the study (CEIC-1410), and all included subjects provided their informed consent at the inclusion.

From the 8330 subjects included in the ILERVAS project, we assessed for eligibility 2411 consecutive subjects who lived near Lleida city. From these subjects, 1408 were excluded, mostly refusal to participate or refusal to repeat invalid sleep study, remaining 1003 subjects with a valid sleep study. Finally, we included a total of 966 individuals who had not been treated previously for OSA and who had a valid sleep study (Fig. 1).

Procedures

Sociodemographic and Clinical Variables

At the inclusion visit on the ILERVAS project, age, sex, ethnicity, clinical history, comorbidities, anthropometric and clinical data were collected and vascular diagnosis tests were performed. Sleepiness was assessed by the Epworth Sleepiness Scale (ESS). Further detailed information about ILERVAS data collection is provided elsewhere.\textsuperscript{14}

Sleep Evaluation

All the subjects included in the current study underwent one-night home cardiorespiratory polygraphy (ApneaLink Air device, Resmed, Sydney, Australia). Further information regarding the device characteristics and the scoring criteria used is provided in the supplemental material.

Based on the results in the sleep study, participants were classified as non-OSA (AHI < 5 events/h) or OSA (AHI ≥ 5 events/h). OSA subjects were classified as having mild (AHI 5–14.9 events/h) or moderate to severe OSA (AHI ≥ 15 events/h).

Atherosclerotic Plaque Evaluation

The presence of atheroma plaques was evaluated by ultrasound in carotid and femoral territories following current guidelines\textsuperscript{14} and atherosclerotic burden was calculated. More details on ultrasound evaluation are provided in supplemental material.

Statistical Analysis

As descriptive analyses, we compared sociodemographic characteristics and sleep parameters across categories of OSA severity groups. Data were described using the median (25–75th percentile) for continuous variables and percentages for categorical variables. The Shapiro–Wilk test was used to evaluate the normality distribution of the data. Differences between groups were assessed using the Kruskal–Wallis test for continuous variables and the Pearson chi-square test for categorical variables. The p for trend was evaluated using the Spearman rank correlation coefficient. The Agresti–Coul intervals were used to report 95% confidence intervals for the prevalence estimations.

The association between OSA severity groups and different cardiovascular risk factors were evaluated using multivariate logistic regression models. Two different adjustments were used. Multivariate logistic regression models were also used to explore the association between the presence of atherosclerotic plaques and the respiratory polygraphy parameters. Additionally, total plaque area was used to explore the association with respiratory polygraphy parameters using multivariable linear regression models. In that case, the distribution of the plaque area was not normal, and log transformation was performed. Models were adjusted using well-established confounding factors such as age, sex, current smoking habit, systolic blood pressure, diastolic blood pressure, total cholesterol, BMI, waist circumference, glycated haemoglobin (HbA1c), and antihypertensive and hypolipidemic treatment. All statistical analyses were conducted using R.\textsuperscript{15} All statistical tests were two-sided, and statistical significance was set at P-value < .05.

Results

Cohort Characteristics

A total of 966 subjects were included (Fig. 1). The main characteristics of the subjects are shown in Table 1. Briefly, the median age
was 57 years (25–75th percentile; 52.0–62.0), the gender ratio was near 1:1 and had a BMI of 28.5 kg/m² (25.6–31.6). The 82% of the included subjects presented 1 or 2 cardiovascular risk factors. At the time of inclusion, hypertension was identified in 39.3% of the subjects; moreover, 30.8% were obese, and 53.7% had dyslipidaemia. Overall, 6.0% had a family history of premature cardiovascular disease. Regarding atherosclerotic burden, the presence of plaque was observed in 70.3% of the subjects. Femoral plaque was the most frequently observed (55.2%).

Prevalence and OSA Characteristics

Globally, 72.6% (95% CI: 69.7%–75.3%) of the subjects had OSA (AHI ≥ 5 events/h). Regarding OSA severity, 35.7% (32.8%–38.8%) of subjects had mild OSA (AHI 5–15 events/h), and 36.9% (33.9%–39.9%) moderate to severe OSA (AHI ≥ 15 events/h). Of these, 14.9% had severe OSA (AHI ≥ 30 events/h).

OSA prevalence was slightly higher in men than in women (79.3% vs. 66.1%). Among moderate to severe OSA subjects, there was a high proportion of men and higher BMI, waist and neck circumference than those subjects with no or mild OSA (Table 1). Regarding sleep parameters, the median AHI was 10.3 (25–75th percentile; 4.5–20.5) events/hour. The median of the mean oxygen saturation was 93% (91%–94%), and the median of the percentage of time with an oxygen saturation < 90% (CT90) was 8.0% (2.0%–27.0%). The median ESS score was 3.5 (2.0–5.0) (Table 2), only 3% of subjects presented an ESS score > 10.

Association Between OSA and Classic Cardiovascular Risk Factors

The association between the presence and severity of OSA and the history of hypertension, obesity, dyslipidaemia, smoking and family history of cardiovascular disease was assessed using logistic regression models with two adjustments, a basic model (age and sex) and an adjusted model (further adjusted for current smoking habit, BMI and neck circumference). The basic model showed a statistically significant association for AHI ≥ 15/h vs AHI < 5/h with a history of hypertension and obesity with an odds ratios (ORs) (95% confidence intervals) of 2.48 (1.72–3.56) and 4.29 (2.86–6.46), respectively. An association between OSA and history of smoking was also observed with an OR of 0.44 (0.31–0.64). Otherwise, no association between OSA and family history of cardiovascular disease and dyslipidaemia was observed, OR 0.89 (0.45–1.80) and 1.35 (0.97–1.88), respectively. These associations were also maintained in the adjusted model with further adjustment variables (Fig. 2).

Relation Between Atherosclerotic Plaque and Sleep Parameters

The association between the presence of atherosclerotic plaque and polygraphy variables was assessed using a multivariate logistic regression model. The presence of femoral and total plaque was associated with CT90 (ORs) 1.015 (1.008–1.023); 1.013 (1.004–1.021), respectively and mean oxygen saturation (0.849 (0.775–0.931); 0.88 (0.797–0.971), respectively). No association was observed between these oximeter variables and the presence of carotid plaque. The AHI, oxygen desaturation index (ODI) and
Fig. 2. Associated risk of OSA with history of hypertension, dyslipidaemia, obesity, smoking and family history of cardiovascular disease. Abbreviations: Family history of cardiovascular disease (FHCVD). Odds ratios (dots) and 95% confidence intervals (lines) are represented. The association between the presence and severity of OSA and the history of hypertension, obesity, dyslipidaemia, smoking and family history of cardiovascular disease was assessed using two logistic regression models: basic model (age and sex) and adjusted model (further adjusting by current smoking habit, BMI and neck circumference).
Table 1
Baseline Characteristics of the Cohort Stratified by the Severity of Obstructive Sleep Apnoea (N = 966).

<table>
<thead>
<tr>
<th></th>
<th>Global N = 966</th>
<th>Non-OSA (AHI &lt; 5) N = 265</th>
<th>Mild OSA (AHI 5–14.9) N = 345</th>
<th>Moderate to Severe OSA (AHI ≥ 15) N = 356</th>
<th>P for Trend</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sociodemographic characteristics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>57.0 [52.0;62.0]</td>
<td>56.0 [52.0;60.0]</td>
<td>57.0 [52.0;62.0]</td>
<td>58.0 [53.0;62.2]</td>
<td>.002</td>
</tr>
<tr>
<td>Sex, female</td>
<td>492 (50.9%)</td>
<td>167 (63.0%)</td>
<td>186 (53.9%)</td>
<td>139 (39.0%)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Tobacco habita</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-smoking</td>
<td>705 (73.0%)</td>
<td>165 (62.3%)</td>
<td>255 (73.9%)</td>
<td>285 (80.1%)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Smoking</td>
<td>261 (27.0%)</td>
<td>100 (37.7%)</td>
<td>90 (26.1%)</td>
<td>71 (19.9%)</td>
<td></td>
</tr>
<tr>
<td><strong>Anthropometric characteristics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>28.5 [25.6;31.6]</td>
<td>26.3 [24.0;29.0]</td>
<td>28.6 [25.7;31.5]</td>
<td>30.0 [27.4;33.3]</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Waist circumference (cm)</td>
<td>100 [91.0;108]</td>
<td>94.0 [88.0;102]</td>
<td>100 [94.0;107]</td>
<td>104 [98.0;112]</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Male &lt; 102 cm; Female &lt; 88 cm</td>
<td>303 (31.4%)</td>
<td>111 (41.9%)</td>
<td>99 (28.7%)</td>
<td>93 (26.1%)</td>
<td></td>
</tr>
<tr>
<td>Male ≥ 102 cm; Female ≥ 88 cm</td>
<td>663 (68.6%)</td>
<td>154 (58.1%)</td>
<td>246 (71.3%)</td>
<td>263 (73.9%)</td>
<td></td>
</tr>
<tr>
<td><strong>History of cardiovascular risk factors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>380 (39.3%)</td>
<td>138 (40.0%)</td>
<td>174 (48.9%)</td>
<td></td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Obesity</td>
<td>298 (30.8%)</td>
<td>106 (30.7%)</td>
<td>150 (42.1%)</td>
<td></td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Dyslipidaemia</td>
<td>519 (53.7%)</td>
<td>182 (52.8%)</td>
<td>206 (57.9%)</td>
<td></td>
<td>.034</td>
</tr>
<tr>
<td>FHCVD</td>
<td>58 (6.0%)</td>
<td>22 (6.4%)</td>
<td>19 (5.3%)</td>
<td></td>
<td>.281</td>
</tr>
<tr>
<td>Smoking</td>
<td>406 (42.0%)</td>
<td>146 (42.3%)</td>
<td>122 (34.3%)</td>
<td></td>
<td>&lt;.001</td>
</tr>
</tbody>
</table>

Results are presented as number of participants (%) and mean [25th percentile; 75th percentile]. Definitions of abbreviations: BMI = Body mass index; FHCVD = Familial history of cardiovascular disease; OSA = Obstructive sleep apnoea. The apnoea–hypopnoea index (AHI) is defined as the number of apnoea and hypopnoea events per hour of study. Non-OSA (AHI < 5), Mild (AHI 5–15), Moderate to severe OSA (AHI ≥ 15).

* Tobacco habit is considered at the time of the initial visit.

b Available data only for patients with presence of plaques.

Table 2
Sleep Characteristics of the Studied Cohort (N = 966).

<table>
<thead>
<tr>
<th></th>
<th>Global N = 966</th>
<th>Non-OSA (AHI &lt; 5) N = 265</th>
<th>Mild OSA (AHI 5–14.9) N = 345</th>
<th>Moderate to Severe OSA (AHI ≥ 15) N = 356</th>
<th>P for Trend</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apnoea–hypopnoea index (events/h)</td>
<td>10.3 [4.5;20.5]</td>
<td>2.6 [1.4;3.9]</td>
<td>9.0 [6.9;11.9]</td>
<td>26.0 [19.3;40.2]</td>
<td>.000</td>
</tr>
<tr>
<td>Apnoea index (events/h)</td>
<td>1.50 [0.45;3.1]</td>
<td>0.3 [0.09;0.9]</td>
<td>1.3 [0.5;2.6]</td>
<td>7.6 [2.7;15.4]</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Hypopnoea index (events/h)</td>
<td>7.7 [3.4;14.7]</td>
<td>1.8 [0.9;2.9]</td>
<td>7.1 [5.2;9.6]</td>
<td>17.9 [13.3;25.9]</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Mean O₂ saturation %</td>
<td>93.0 [91.0;94.0]</td>
<td>94.0 [93.0;94.0]</td>
<td>93.0 [92.0;94.0]</td>
<td>92.0 [91.0;93.0]</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Minimum O₂ saturation %</td>
<td>83.0 [79.0;86.0]</td>
<td>87.0 [83.0;89.0]</td>
<td>83.0 [80.0;86.0]</td>
<td>79.0 [73.0;82.2]</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>CT90%</td>
<td>8.0 [2.0;27.6]</td>
<td>1.0 [0.0;6.0]</td>
<td>6.0 [2.2;20.0]</td>
<td>2.2 [8.8;41.0]</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Epworth Sleepiness Scale (ESS) score</td>
<td>3.50 [2.0;5.00]</td>
<td>3.00 [2.0;5.00]</td>
<td>3.00 [2.0;5.00]</td>
<td>4.00 [2.0;6.00]</td>
<td>.004</td>
</tr>
</tbody>
</table>

Results are presented as the median [25th percentile; 75th percentile]. Definitions of abbreviations: CT90=percentage of time with an oxygen saturation <90%; OSA=Obstructive sleep apnoea. The apnoea–hypopnoea index (AHI) is defined as the number of apnoea and hypopnoea events per hour of study. Non-OSA (AHI <5), Mild (AHI 5–15), Moderate to severe OSA (AHI ≥ 15).

a Available data for n = 776.

Discussion

The present study confirms a high prevalence of OSA in subjects with mild–moderate cardiovascular risk and shows an association between the presence of atherosclerotic disease and parameters of nocturnal oxygen saturation.

To the best of our knowledge, our study is the first to evaluate the prevalence of OSA in a well-characterized cohort of middle-aged subjects with mild–moderate cardiovascular risk. Our findings show that the overall prevalence of OSA is 72.6%, being the prevalence of mild OSA 35.7%, and the prevalence of moderate to severe OSA 36.9%. OSA prevalence in our study is higher than previously reported in the general population; nevertheless, it is difficult to compare among studies because of different types of sleep studies and different criteria to score and define OSA.

To date, a wide range of OSA prevalence has been reported, even when the same AHI cut-off point was used to define OSA. We observe that in a study performed in Hispanic subjects, the total prevalence of OSA was 25.8%, of which 9.8% for moderate OSA and 3.9% for severe OSA. Peppard et al. reported an estimated prevalence of OSA of 36.6% and 20.2% in men and women, respectively. Considering that age range and BMI were similar to our cohort, the prevalence observed in our study is higher than that described by Peppard et al. for both sexes. However, our prevalence is lower than reported by Heiner. Differences could be explained by the use of polysomnography and the percentage of symptomatic subjects included in their study. Therefore, com-
Moreover, and although they establish a subclinical association without excluding other factors, it cannot be denied that a smoking patient presents tobacco as the only risk factor while non-smoking patients were included in the study for presenting other cardiovascular risk factors and therefore we cannot exclude a selection bias that could have influenced the results.

Atherosclerotic burden, total and femoral plaque were associated with CT90 and mean oxygen saturation but not with AHI, minimal oxygen saturation or ODI. Our results are in line with previous studies linking mean oxygen saturation and CT90 with subclinical atherosclerosis.12,23–27 Unlike other studies,13,28,29 we did not find a relationship between AHI and the presence of plaque or the atherosclerotic burden in any territory. Our results are consistent with previous studies describing an association between atherosclerotic disease and OSA-related hypoxaemia parameters without an association with the AHI.10 and indicate, as previously described, that atherosclerosis could be more strongly associated with hypoxaemia than with episodes of obstruction (represented by AHI).12,23,24 CT90 has been described as the strongest predictor of subclinical atherosclerosis25 and several observational studies showed that CT90 and mean SaO2 better predict cardiovascular mortality than the AHI.30,31

Moreover, our results are in line with recent publications indicating that the assessment of the severity of OSA only with the AHI could be insufficient as it measures the frequency of respiratory events but does not include key aspects of the deleterious effect of OSA on the cardiovascular system such as the duration and severity of the gasometrical changes. In this sense, Azarbarzin et al. have recently shown that the “hypoxic burden”, a new measure of OSA severity related to oxygenation changes associated with the respiratory events, could be more relevant to assess the relationship between OSA and cardiovascular disease than the AHI.22

It is important to note that CT90 can characterize not only nocturnal hypoxaemia associated with obstructive events but also persistent hypoxaemia that could be related to other conditions such as chronic respiratory diseases. In our cohort, CT90 values increase progressively as the severity of OSA (established by the AHI) increases. This fact suggests that CT90 reflects hypoxaemia related to OSA and not due to other underlying respiratory diseases such as COPD. Moreover, subjects included in the study presented spirometry values within the normal range. The mean CT90 value in our cohort was 8%. Even though it is not a high value, an association between CT90 and markers of atherosclerotic disease23 and CV mortality33 have been described with values of lower magnitude.

Differences between arterial territories were observed. An association between nocturnal hypoxaemia and atherosclerosis in femoral arteries was reported, while no association between carotid territory plaques and any polygraphy variables was found. Our results are consistent with studies showing an association between OSA and peripheral arterial disease34 and are in line with previous studies not showing an association between OSA and carotid atheromatosis; territory in which controversy on the effect of OSA exists.28,35,36

Unlike our study, authors usually do not evaluate the presence of atherosclerosis in different territories and therefore evidence on the chronology and the territory mostly affected in OSA is scare. In studies assessing carotid and femoral territories in general population of similar characteristics than our patients, it has been described that femoral atherosclerosis could be an early marker of subclinical atherosclerosis37 and therefore it is possible that OSA related-hypoxia may have a greater impact on the territory with earlier affectation.

Multiple factors intervene in the generation of atherosclerosis and their interaction with OSA related hypoxaemia probably could influence differently the atherosclerotic process in carotid and femoral territories. The risk factors for atherosclerosis in the two areas (carotid and femoral) are similar,38,39 although peripheral arterial disease seems to be more dependent on smoking habits38 than carotid disease. Therefore, with the results, we can hypothesize that hypoxia may have a greater synergistic effect to

Table 3
Association Between Atherosclerotic Plaques and Sleep Parameters.

<table>
<thead>
<tr>
<th>Presence of Atherosclerotic Disease</th>
<th>Carotid Plaque (N=966)</th>
<th>Femoral Plaque (N=966)</th>
<th>Total Plaque (N=966)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR (95%CI)</td>
<td>P Value</td>
<td>OR (95%CI)</td>
</tr>
<tr>
<td>Apnoea–hypopnoea index (events/h)</td>
<td>1.006 (0.995,1.015)</td>
<td>.197</td>
<td>0.997 (0.987,1.006)</td>
</tr>
<tr>
<td>CT90%</td>
<td>1.006 (0.999,1.013)</td>
<td>.061</td>
<td>1.015 (1.008,1.023)</td>
</tr>
<tr>
<td>Minimum O2 saturation %</td>
<td>0.983 (0.963,1.004)</td>
<td>.111</td>
<td>0.985 (0.963,1.007)</td>
</tr>
<tr>
<td>Mean O2 saturation %</td>
<td>0.925 (0.851,1.007)</td>
<td>.073</td>
<td>0.849 (0.775,0.931)</td>
</tr>
<tr>
<td>Oxygen desaturation index 3%</td>
<td>1.008 (0.998,1.017)</td>
<td>.106</td>
<td>0.998 (0.988,1.007)</td>
</tr>
</tbody>
</table>

Total Plaque Area

<table>
<thead>
<tr>
<th></th>
<th>Carotid Plaque Area (N=468)</th>
<th>P Value</th>
<th>Femoral Plaque Area (N=533)</th>
<th>P Value</th>
<th>Total Plaque Area (N=679)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apnoea–hypopnoea index (events/h)</td>
<td>0.998 (0.993,1.003)</td>
<td>.537</td>
<td>1.001 (0.997,1.006)</td>
<td>.546</td>
<td>0.999 (0.994,1.004)</td>
<td>.649</td>
</tr>
<tr>
<td>CT90%</td>
<td>1.002 (0.998,1.006)</td>
<td>.354</td>
<td>1.004 (1.001,1.007)</td>
<td>.030</td>
<td>1.005 (1.002,1.009)</td>
<td>.003</td>
</tr>
<tr>
<td>Minimum O2 saturation %</td>
<td>0.999 (0.987,1.101)</td>
<td>.882</td>
<td>0.987 (0.977,0.998)</td>
<td>.020</td>
<td>0.994 (0.982,1.005)</td>
<td>.255</td>
</tr>
<tr>
<td>Mean O2 saturation %</td>
<td>0.979 (0.933,1.027)</td>
<td>.388</td>
<td>0.945 (0.907,0.984)</td>
<td>.007</td>
<td>0.932 (0.892,0.974)</td>
<td>.002</td>
</tr>
<tr>
<td>Oxygen desaturation index 3%</td>
<td>0.999 (0.994,1.004)</td>
<td>.748</td>
<td>1.002 (0.997,1.006)</td>
<td>.504</td>
<td>0.9995 (0.995,1.005)</td>
<td>.866</td>
</tr>
</tbody>
</table>

The association between the presence of atherosclerotic disease and the polygraph variables has been evaluated with a logistic regression model. The association of the total plaque with the polygraph variables has been evaluated using a linear regression model. Both models were adjusted by sex, age, current smoking habit, systolic blood pressure, diastolic blood pressure, total cholesterol, BMI, waist circumference, antihypertensive treatment, HbA1c, and hypopilidemic treatment. CT90 = percentage of time with an oxygen saturation <90%; The apnoea–hypopnoea index (AHI) is defined as the number of apnoea and hypopnoea events per hour of study. a log transformed outcome. For each one-unit increase in the sleep parameters, the atherosclerotic plaque area changes by approximately (e0.1 − 1) × 100%
promote atherosclerosis when interacting with the risk factors for peripheral arterial disease such as tobacco. In contrast with previous data,35 our results suggest that vibration produced by snoring may not have an important role in the generation of carotid plaque.

The main strength of our study is that it was performed in a large and well-characterized cohort of subjects with mild–moderate cardiovascular risk in which both arterial territories were evaluated.

Some limitations should be mentioned. First, the cross-sectional design limits causal inferences. Second, history of cardiovascular risk factors was not assessed at the same time than the sleep study and it could make associations less robust and difficult to establish causality, therefore the results should be extrapolated with caution. Third, subjects included are of a specific age group and the results cannot be extrapolated to other age groups. Additionally, age range was slightly different according to sex, making difficult to compare both groups. Forth, OSA diagnosis was performed using a simplified method; therefore, OSA prevalence can be underestimated and subjects misclassified. In addition, this simplified method does not provide information related to sleep structure, sleep fragmentation and arousal index, factors that have been related to atherosclerosis.

Conclusion

In conclusion, our study shows a high prevalence of OSA in patients with mild–moderate cardiovascular risk. Moreover, the study shows an association between the atherosclerotic burden, total and femoral plaque with CT90 and mean oxygen saturation, suggesting the importance of OSA-related hypoxaemia in the induction of atherosclerotic disease.

Our data encourage clinicians to perform an energetic intervention to diagnose and control OSA in patients with cardiovascular risk factors. Future randomized clinical trials performed in well-characterized subjects according to their atheromatous risk are needed to evaluate if treating OSA could be beneficial and establish if subjects with subclinical arterial disease could be a target population.

Founding Source

This work was supported by Diputació de Lleida, Instituto de Salud Carlos III [RETIC RD16/0009/0011]; Ministerio de Ciencia, Innovación y Universidades [JCI2018-037792-I]; Fondos recibidos por el ISCIII y fondos FEDER “Una manera de hacer Europa” [P19/00907]; Oxigen Salud; Resmed; Jordi de Batlle acknowledges receiving financial support from Instituto de Salud Carlos III [ISCIII; Miguel Servert 2019: CP19/00108] and co-funded by European Regional Development Fund (ERDF)/European Social Fund (ESF), “Investing in your future”.

Conflict of Interest

All authors declare that there is no conflict of interest

Acknowledgements

The authors want to thank to IRBLEida Biobank (B.00000682) and PLATAFORMA BIOPANCOS PT17/0015/0027 for their technical support.

The authors of the manuscript want to thank to ILERVAS Group: Eva Castro-Boqué, Montserrat Martínez-Alonso, Didac Mauricio, Pere Godoy, Manuel Sánchez-de-la-Torre, Manuel Portero-Otín, Eva Miquel, Marta Ortega, Jessica González, Silvia Barril, Mariona Jové, Marta Hernández, Ferran Rius Riu, Josep Franch-Nadal, Esmeralda Castelblanco, and Francisco Purroy.

Appendix A. Supplementary Data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.arbres.2021.01.026.

References


